
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Jan 15, 2026 07:02 am UTC| Business Health Governance
Sanofi SA (EPA: SASY) has achieved a significant regulatory milestone in China after receiving approval for two of its specialty medications, Myqorzo and Redemplo. The approvals mark an important step in expanding Sanofis...

Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Jan 13, 2026 02:34 am UTC| Business Health
Merck announced on Monday that it has significantly raised its long-term growth outlook, projecting up to $70 billion in revenue from new growth drivers by the mid-2030s. The updated forecast highlights the pharmaceutical...

Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Jan 13, 2026 02:24 am UTC| Health Business
Viking Therapeutics CEO Brian Lian said pharmaceutical companies are showing broader and deeper strategic interest in weight-loss drug deals than is immediately visible, as the global obesity treatment market continues to...

Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Jan 08, 2026 02:48 am UTC| Law Politics Business Health
A federal appeals court has blocked a Trump administration initiative that would have required hospitals serving low-income Americans to pay full prices upfront for certain high-cost prescription drugs before receiving...

Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing
Jan 06, 2026 02:27 am UTC| Business Health
Danish pharmaceutical giant Novo Nordisk has officially launched its once-daily Wegovy weight-loss pill in the United States, intensifying competition in the rapidly growing obesity drug market. The oral medication,...

Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Dec 31, 2025 01:51 am UTC| Business Health
Novo Nordisk and Eli Lilly are significantly lowering prices of their blockbuster obesity drugs Wegovy and Mounjaro in China, a move aimed at expanding access in one of the worlds fastest-growing weight-loss markets and...

Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Dec 31, 2025 01:47 am UTC| Governance Business Health
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more...